Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:INDV NASDAQ:MOR NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.72$19.32$16.65▼$31.26$825.37M0.89410,990 shs445,683 shsINDVIndivior$40.53$38.87$16.69▼$42.81$4.94B0.861.53 million shs837,410 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AVKTXViking Therapeutics$34.79$33.79$22.96▼$43.15$4.04B0.662.17 million shs1.84 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%-5.22%-14.05%-13.53%-16.32%INDVIndivior0.00%-0.02%-3.11%+18.13%+136.46%MORMorphoSys0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics0.00%-6.18%-8.54%+5.46%+1.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.72$19.32$16.65▼$31.26$825.37M0.89410,990 shs445,683 shsINDVIndivior$40.53$38.87$16.69▼$42.81$4.94B0.861.53 million shs837,410 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AVKTXViking Therapeutics$34.79$33.79$22.96▼$43.15$4.04B0.662.17 million shs1.84 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%-5.22%-14.05%-13.53%-16.32%INDVIndivior0.00%-0.02%-3.11%+18.13%+136.46%MORMorphoSys0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics0.00%-6.18%-8.54%+5.46%+1.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.75Reduce$22.0017.52% UpsideINDVIndivior 2.71Moderate Buy$43.677.74% UpsideMORMorphoSys 0.00N/AN/AN/AVKTXViking Therapeutics 2.67Moderate Buy$97.00178.82% UpsideCurrent Analyst Ratings BreakdownLatest VKTX, MOR, AMPH, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)7/21/2026AMPHAmphastar Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/20/2026VKTXViking Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026VKTXViking Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)7/8/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)6/29/2026AMPHAmphastar Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$25.00 ➝ $20.006/29/2026INDVIndivior Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/23/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)6/22/2026AMPHAmphastar Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/18/2026INDVIndivior BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$46.00(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.15$4.25 per share4.40$17.17 per share1.09INDVIndivior$1.24B3.99$2.72 per share14.90($0.78) per share-51.96MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17VKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6611.286.713.6811.00%15.12%7.14%8/6/2026 (Estimated)INDVIndivior$210M$1.9520.789.49N/A19.44%-219.26%29.40%8/4/2026 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AVKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest VKTX, MOR, AMPH, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AMPHAmphastar Pharmaceuticals$0.66N/AN/AN/A$179.92 millionN/A8/4/2026Q2 2026INDVIndivior$0.9220N/AN/AN/A$307.55 millionN/A7/29/2026Q2 2026VKTXViking Therapeutics-$1.21N/AN/AN/AN/AN/A5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82INDVIndiviorN/A0.860.66MORMorphoSys4.981.381.38VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%INDVIndivior60.33%MORMorphoSys18.38%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%INDVIndivior0.74%MORMorphoSys0.05%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableVKTX, MOR, AMPH, and INDV HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Increases Stock Position in Viking Therapeutics, Inc. $VKTXJuly 25 at 6:31 AM | marketbeat.comHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23, 2026 | finance.yahoo.comViking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Comes Into ViewJuly 23, 2026 | finance.yahoo.comViking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy NewsJuly 23, 2026 | finance.yahoo.comHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23, 2026 | zacks.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23, 2026 | finance.yahoo.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23, 2026 | prnewswire.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22, 2026 | finance.yahoo.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22, 2026 | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Rating Lowered to "Strong Sell" at Zacks ResearchJuly 22, 2026 | marketbeat.comViking Therapeutics (VKTX) to Release Earnings on WednesdayJuly 22, 2026 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Crosses Above 50 Day Moving Average - Here's What HappenedJuly 22, 2026 | marketbeat.comKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmJuly 21, 2026 | prnewswire.comHead-To-Head Analysis: Capstone Therapeutics (NASDAQ:CAPS) vs. Viking Therapeutics (NASDAQ:VKTX)July 21, 2026 | americanbankingnews.comWatch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1July 18, 2026 | fool.comShould You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.July 18, 2026 | fool.comViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteJuly 17, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteJuly 17, 2026 | zacks.comViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?July 17, 2026 | finance.yahoo.comViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?July 17, 2026 | zacks.comThe weight-loss drugs boom is creating both winners and wipeouts: One Big Investment IdeaJuly 17, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026SanDisk’s Volatility May Be Telling Bulls What They Want to HearBy Sam Quirke | July 2, 2026Is the Memory Rally Still Alive After the Semiconductor Sell-Off?By Jessica Mitacek | July 2, 2026Apple Just Handed These 4 Memory Stocks Their Best News of the YearBy Bridget Bennett | June 28, 2026VKTX, MOR, AMPH, and INDV Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$18.72 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$18.68 -0.04 (-0.24%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Indivior NASDAQ:INDV$40.53 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$40.52 -0.01 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/24/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Viking Therapeutics NASDAQ:VKTX$34.79 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.06 +0.27 (+0.76%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
